Oxford BioMedica Confirms Private Equity Takeover Talks

Why It Matters

A potential EQT takeover could take Oxford Bio private, reshaping European biotech CDMO ownership and unlocking capital for further CGT scale‑up. It also highlights growing private‑equity appetite for high‑growth gene‑therapy manufacturing assets.

Key Takeaways

• EQT made unsolicited cash offer for Oxford BioMedica.
• Shares jumped 15% after approach confirmation.
• Revenue grew 44% to £73 million last year.
• US expansion includes viral‑vector facility in North Carolina.
• Valuation sits around £1 billion ahead of proposal deadline.

Pulse Analysis

Oxford BioMedica has emerged as a pivotal player in the cell and gene therapy (CGT) supply chain, leveraging its UK base and recent US foothold to meet soaring demand for viral‑vector products. The company’s 44% revenue surge to £73 million, coupled with a doubled order book of £149 million, underscores the rapid commercialization of gene‑editing treatments and the strategic importance of scalable manufacturing platforms. Recent acquisitions, notably the ABL Europe purchase and the North Carolina viral‑vector plant, have broadened its service portfolio and geographic reach, positioning it as a go‑to CDMO for biotech firms seeking end‑to‑end development.

The unsolicited approach by EQT reflects a broader wave of private‑equity interest in European biotech firms perceived as undervalued relative to their growth prospects. By targeting Oxford Bio, EQT aims to consolidate a high‑margin, technology‑intensive asset that can benefit from deeper pockets and operational expertise. The firm’s requirement to submit a binding offer by 11 February adds a time‑sensitive dimension, while the £1 billion valuation signals a premium over recent market prices, suggesting that any deal could deliver a substantial windfall for shareholders.

Should the transaction proceed, the likely delisting of Oxford Bio would provide EQT with the flexibility to accelerate capital investment, streamline governance, and potentially pursue further acquisitions to build a pan‑European CGT manufacturing platform. For the industry, this could intensify competition among CDMOs, drive down contract pricing, and spur innovation in vector design and production efficiency. Conversely, a failed bid would keep the company public, preserving current shareholder liquidity but possibly limiting the scale of future funding needed to meet the expanding pipeline of gene‑therapy candidates.